
Sign up to save your podcasts
Or


Melanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics interviews Holly Krasa, CEO of Blue Persimmon Group. In this episode they discuss the recent CPE Exclusive: Cobenfy™ for Adults Living with Schizophrenia, the need for innovation in schizophrenia, and the importance of listening to the stories from people living with schizophrenia.
By Leerink PartnersMelanie Whittington, PhD, Head of the Leerink Center for Pharmacoeconomics interviews Holly Krasa, CEO of Blue Persimmon Group. In this episode they discuss the recent CPE Exclusive: Cobenfy™ for Adults Living with Schizophrenia, the need for innovation in schizophrenia, and the importance of listening to the stories from people living with schizophrenia.